found that among patients with a history of CRA, the use of rofecoxib, a selective COX-2 inhibitor, was associated with an increased cardiovascular risk, including myocardial infarctions and ischemic cerebrovascular events, and the increased relative risk of thrombotic events was first observed after approximately 18 months of treatment (19). The gene discussed is PTGS2; the disease is myocardial infarction.